Dr. Susan Alpert, MD, PhD, has been named, Lead Regulatory Consultant for Cognos Therapeutics, Inc. Dr. Alpert is considered one of the top U.S. regulatory experts.
Cognos Therapeutics believes its SINNAIS implantable pump can increase efficacy of CAR T therapies for the treatment of leukemia.
Cognos Therapeutics plans to conduct a twenty-patient human clinical trial using direct delivery of Herceptin (a Genentech drug) to prove drug safety in the brain region.
Cognos Therapeutics plans to conduct a 20-patient human clinical trial for direct delivery of Herceptin using the Sinnais implantable pump.
Dr. Francis Ali-Osman speaks at the Hancock Symposium at Westminster Collage on the state of cancer research and treatment.
FDA’s Role In The Precision Medicine Initiative Pushes Combination Drug Devices to New Heights Sharing Cognos Therapeutics Vision.
Cognos Therapeutics’ Sinnais drug delivery technology is poised to meet the need for Companion Diagnostic modalities.